2019
2797 Fenofibrate and PSC: A Case Series From a Single Center Liver Registry
Shah S, Silveira M, Assis D, Cusack L. 2797 Fenofibrate and PSC: A Case Series From a Single Center Liver Registry. The American Journal Of Gastroenterology 2019, 114: s1544-s1545. DOI: 10.14309/01.ajg.0000600720.33625.bb.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisPrimary biliary cholangitisCase seriesUrsodeoxycholic acidLarge-duct primary sclerosing cholangitisTreatment of primary sclerosing cholangitisNo current effective therapyRetrospective single-center case seriesPrimary sclerosing cholangitis patientsSingle-center case seriesAlkaline phosphataseRisk scorePrimary sclerosing cholangitis treatmentPost-FFSAlkaline phosphatase reductionPatients due to lackAcute kidney injuryCholestatic liver diseaseAlkaline phosphatase levelsCurrent effective therapiesSerum alkaline phosphataseInflammatory bowel diseaseIntrahepatic diseaseAutoimmune hepatitisRecurrent cholangitisEffects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Group I, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2019, 18: 179-187.e6. PMID: 31100458, PMCID: PMC6941216, DOI: 10.1016/j.cgh.2019.05.013.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseaseEffect of vedolizumabSerum levelsLast followSclerosing cholangitisBowel diseaseStudy groupInternational PSC Study GroupAlkaline phosphataseLiver-related eventsLiver-related outcomesPresence of cirrhosisProportion of patientsSubset of patientsMedian serum levelsAnalysis of patientsInternational Study GroupLarge international cohortNorth American centersBacterial cholangitisCirrhosis decompensationEntire cohortClinical dataIntegrin α4β7
2017
Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis
Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAlanine TransaminaseAlkaline PhosphataseBile Acids and SaltsCholagogues and CholereticsCholangitis, SclerosingCholestenonesDrug Therapy, CombinationFemaleHumansLiverLiver Function TestsMaleMiddle AgedPilot ProjectsTreatment OutcomeTretinoinUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisUrsodeoxycholic acidAlanine aminotransferaseUDCA monotherapyPrimary endpointSclerosing cholangitisMedian serum alanine aminotransferasePilot studyWeeks of therapyMarkers of inflammationSerum alanine aminotransferaseRetinoic acidAlkaline phosphataseAll-Trans Retinoic AcidSerum ALP levelsHuman pilot studyCombination of ATRAAddition of ATRABile acid synthesisTrans retinoic acidExploratory pilot studyALT levelsAccepted therapyWeek 12C4 levels